摘要
目的 探讨血清糖链抗原 5 0 (CA5 0 )对肝癌的诊断及其作为肿瘤标志物的临床诊断价值。 方法 选择良、恶性肝病为研究对象 ,检测慢性肝炎、肝硬化及肝癌患者血清 CA5 0含量 ,并与肝功能及血清 AFP含量进行比较。 结果 以正常对照均值 +2标准差为标准 ,乙型肝炎患者血清 CA5 0阳性者占 5 0 % ,其中肝硬化患者 CA5 0阳性者占6 7.7% ,原发性肝癌患者占 95 .1%。而 36例血清 AFP<2 0 0 ug/L 的原发性肝癌患者有 32例 CA5 0阳性 (88.9% )。 结论 血清 CA5 0检测能提高 AFP浓度升高不明显或 AFP阴性的肝癌患者的诊断率 ;检测血清 CA5 0含量作为诊断肝癌及其它恶性肿瘤的标志物时应考虑慢性良性肝病的假阳性。
Objective To study the diagnosis values of detection of serum carbongydrate antigen 50 (CA50) levels in patients with malignant trmors. Methods Serum concentrations of CA50 and its relationship with AFP and ALT were simultaneously investigated in patients with chronic non-malignant diseases of the liver and primary hepatocarcinoma(PHC). Result The positivity rates of serum CA50 were as follow: 50% in chronic hepatitis; 67.7% in liver cirrhosis(LC); 95.1% in PHC and 88.9% in AFP negative patients with PHC. Conclusion Detection of serum CA50 are of certain value for clinical diagnosis of AFP negative patients with PHC. The false positivity rates of chronic benign liver diseases should be paid attention wheh serum concentrations of CA50 were used as a valuable marker in patients with PHC or other malignant tumors.
出处
《实用预防医学》
CAS
2001年第1期13-14,共2页
Practical Preventive Medicine
